학술논문
Letter to the editor.
Document Type
Editorial & Opinion
Author
Fraiman J; Baromedical Research Institute, New Orleans, LA, USA.; Erviti J; Unit of Innovation and Organization, Navarre Health Service, Spain.; Jones M; Institute of Evidence-Based Healthcare, Bond University, Gold Coast, QLD, Australia.; Greenland S; Fielding School of Public Health and College of Letters and Science, University of California, Los Angeles, CA, USA.; Whelan P; Geffen School of Medicine, University of California, Los Angeles, CA, USA.; Kaplan RM; Clinical Excellence Research Center, School of Medicine, Stanford University, CA, USA.; Doshi P; University of Maryland School of Pharmacy, Baltimore, MD, USA. Electronic address: pdoshi@rx.umaryland.edu.
Source
Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
Subject
Language
English
Abstract
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: JF, JE, MJ, SG, PW, RK: none to declare. PD has received travel funds from the European Respiratory Society (2012) and Uppsala Monitoring Center (2018); grants from the FDA (through University of Maryland M-CERSI; 2020), Laura and John Arnold Foundation (2017–22), American Association of Colleges of Pharmacy (2015), Patient-Centered Outcomes Research Institute (2014–16), Cochrane Methods Innovations Fund (2016–18), and UK National Institute for Health Research (2011–14); was an unpaid IMEDS steering committee member at the Reagan-Udall Foundation for the FDA (2016–2020) and is senior editor, investigations, The BMJ. The views and opinions do not necessarily reflect the official policy or position of the University of Maryland.